v3.24.0.1
Guide Acquisition - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Feb. 23, 2021
Dec. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]        
Value of shares issued for upfront payment of acquisition   $ 120,032    
Research and development expense   154,953    
Contingent consideration liabilities     $ 2,723 $ 12,463
Common Stock        
Business Acquisition [Line Items]        
Value of shares issued for upfront payment of acquisition   $ 10    
Guide Therapeutics, Inc. | Merger Agreement        
Business Acquisition [Line Items]        
Business Acquisition, merger agreement date Feb. 23, 2021      
Business combination upfront consideration paid in common stock $ 120,000      
Value of shares issued for upfront payment of acquisition 120,000      
Research and development expense 155,000      
Contingent consideration liabilities $ 36,500      
Guide Therapeutics, Inc. | Merger Agreement | Common Stock        
Business Acquisition [Line Items]        
Number of shares issued for upfront payment of acquisition 1,087,153      
Guide Therapeutics, Inc. | Merger Agreement | Technology Milestones | Maximum | Former Stockholders and Optionholders        
Business Acquisition [Line Items]        
Potential milestone payable in form of common stock $ 100,000      
Guide Therapeutics, Inc. | Merger Agreement | Product Milestones | Maximum | Former Stockholders and Optionholders        
Business Acquisition [Line Items]        
Potential milestone payable in form of common stock $ 220,000